Researchers looked at a blood measure called the albumin-corrected anion gap (ACAG) in patients with chronic kidney disease. The study included 973 patients from one hospital in China who had a procedure to open blocked heart arteries. They were followed for about two and a half years on average. The goal was to see if this blood test result was linked to future heart problems.
The main finding was that patients with a higher ACAG level had more major heart events. These events included heart-related death, another heart attack, or a non-fatal stroke. About 30% of people in the high ACAG group had one of these events, compared to about 16% in the low ACAG group. The study did not report on specific safety concerns or side effects related to the test itself.
It is important to be careful with these results. This was a retrospective study, meaning researchers looked back at old medical records. This type of study can show a link, but it cannot prove that a high ACAG causes heart problems. Also, because it was done at just one hospital, the results might not apply to everyone. Readers should see this as an early finding that points to a potential new area for doctors to watch. More research is needed to confirm if this blood test is truly useful for predicting risk.